Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

ClinicalTrials.gov ID: NCT04545060

Public ClinicalTrials.gov record NCT04545060. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II/III Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase 2/3 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 or placebo and will be assessed for safety, tolerability, efficacy, and pharmacokinetics.

Study identification

NCT ID
NCT04545060
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Vir Biotechnology, Inc.
Industry
Enrollment
1,057 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 26, 2020
Primary completion
Apr 7, 2021
Completion
Sep 1, 2021
Last update posted
Nov 6, 2022

2020 – 2021

United States locations

U.S. sites
63
U.S. states
20
U.S. cities
52
Facility City State ZIP Site status
Investigative Site Anniston Alabama 36207
Investigative Site Cullman Alabama 35055
Investigative Site Mesa Arizona 85210
Investigative Site Tucson Arizona 85712
Investigative Site Los Angeles California 90017
Investigative Site Los Angeles California 90036
Investigative Site Northridge California 91325
Investigative Site Oxnard California 93030
Investigative Site Rolling Hills Estates California 90274
Investigative Site Sacramento California 95817
Investigative Site Doral Florida 33166
Investigative Site Gainesville Florida 32607
Investigative Site Hialeah Florida 33016
Investigative Site Miami Florida 33122
Investigative Site Miami Florida 33125
Investigative Site Miami Florida 33155
Investigative Site Miami Florida 33173
Investigative Site Miami Florida 33186
Investigative Site Miramar Florida 33027
Investigative Site North Miami Florida 33169
Investigative Site Palmetto Bay Florida 33157
Investigative Site Pembroke Pines Florida 33024
Investigative Site Pompano Beach Florida 33064
Investigative Site Tampa Florida 33614
Investigative Site Tampa Florida 33615
Investigative Site Atlanta Georgia 30315
Investigative Site Atlanta Georgia 30318
Investigative Site Decatur Georgia 30030
Investigative Site Stockbridge Georgia 30281
Investigative Site Idaho Falls Idaho 83404
Investigative Site Mishawaka Indiana 46544
Investigative Site Lake Charles Louisiana 70601
Investigative Site Marrero Louisiana 70072
Investigative Site Baltimore Maryland 21230
Investigative Site Caro Michigan 48723
Investigative Site Hazelwood Missouri 63042
Investigative Site Las Vegas Nevada 89109
Investigative Site Las Vegas Nevada 89130
Investigative Site Santa Fe New Mexico 87505
Investigative Site The Bronx New York 10456
Investigative Site Asheboro North Carolina 27203
Investigative Site Charlotte North Carolina 28208
Investigative Site Columbus Ohio 43215
Investigative Site Smithfield Pennsylvania 15478
Investigative Site Chattanooga Tennessee 37421
Investigative Site Austin Texas 78705
Investigative Site Baytown Texas 77521
Investigative Site Beaumont Texas 77702
Investigative Site Dallas Texas 75231
Investigative Site Denton Texas 76210
Investigative Site El Paso Texas 79935
Investigative Site Forney Texas 75126
Investigative Site Houston Texas 77017
Investigative Site Houston Texas 77024
Investigative Site Houston Texas 77058
Investigative Site Houston Texas 77090
Investigative Site Humble Texas 77338
Investigative Site Laredo Texas 78041
Investigative Site McAllen Texas 78504
Investigative Site Mesquite Texas 75149
Investigative Site Sugar Land Texas 77478
Investigative Site Kirkland Washington 98034
Investigative Site Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04545060, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2022 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04545060 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →